Market Access News | pharmaphorum

News

NICE backs NHS use for Astellas' Xospata after rethink

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia

News

Mallinckrodt’s liver disease drug terlipressin edges FDA adv...

An FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type 1 (HRS-1), after the agency questioned the findi

News

UK patients get early access to Alnylam's ultra-rare disease...

The UK's regulator has granted early access to Alnylam's ultra-rare disease drug lumasiran, allowing patients with primary hyperoxaluria type 1 to gain access ahead of a regulatory decision

News

FDA reviewer warns of eye trouble with GSK’s myeloma ADC

GlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for multiple myeloma – with a question about safety h

News

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form of non-Hodgkin lymphoma (NHL), says NICE.

News

US snaps up first supplies of Regeneron’s COVID-19 antibody

Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first

NICE backs NHS use for Astellas' Xospata after rethink

Mallinckrodt’s liver disease drug terlipressin edges FDA adv...

UK patients get early access to Alnylam's ultra-rare disease...

FDA reviewer warns of eye trouble with GSK’s myeloma ADC

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

US snaps up first supplies of Regeneron’s COVID-19 antibody

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks